

### **CERTIFICATE OF ANALYSIS**

Page 1 of 2

**Product Description:** V-PLEX® SARS-CoV-2 Panel 17 Kit

Kit Catalog Numbers: K15524-Series, K15525-Series, K15526-Series, K15527-Series; K15528-

Series; K15529-Series; K15530-Series

**Kit Lot Number**: K0082052 **Expiration Date**: 31 JAN 2024

# **Kit Components:**

Description	Lot Number	<b>Storage Temperature</b>	<b>Expiration Date</b>
SARS-CoV-2 Plate 17	Z0057190	2-8°C	30 NOV 2024
Reference Standard 1	A0080286	≤ -70°C	28 FEB 2026
Serology Control 1.1	A00C0825	≤ -70°C	31 MAR 2027
Serology Control 1.2	A00C0826	≤ -70°C	31 MAR 2027
Serology Control 1.3	A00C0827	≤ -70°C	31 MAR 2027
SULFO-TAG™ Human ACE2 Protein	D0081760	2-8°C	31 JAN 2024
ACE2 Calibration Reagent	A0080301	2-8°C	31 MAR 2025
SULFO-TAG™ Anti-Human IgG Antibody	D00V0025	2-8°C	30 SEP 2025
SULFO-TAG™ Anti-Human IgM Antibody	Not Kit Specific	2-8°C	See Label
SULFO-TAG™ Anti-Human IgA Antibody	Not Kit Specific	2-8°C	See Label
SULFO-TAG™ Anti-Mouse IgG Antibody	Not Kit Specific	2-8°C	See Label
SULFO-TAG <sup>TM</sup> Anti-Mouse IgM Antibody	Not Kit Specific	2-8°C	See Label
SULFO-TAG™ Anti-Mouse IgA Antibody	Not Kit Specific	2-8°C	See Label
Diluent 100	Not Kit Specific	2-8°C	See Label
MSD Blocker A Kit	Not Kit Specific	Room Temperature	See Label
MSD GOLD Read Buffer B	Not Kit Specific	Room Temperature	See Label

See product insert regarding which components are provided with each IgG, IgA, IgM, or ACE2 kit.

# **Plate Uniformity Testing Results:**

Parameter	Precision			Uniformity	Signal
Metric	CV of Intra- plate Averages	Average Intra- plate CV	Max Intra- plate CV	Average Uniformity Metric	Average Signal
SARS-CoV-2 Spike	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (D614G)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 - 1,000,000
SARS-CoV-2 Nucleocapsid	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 - 1,000,000
SARS-CoV-2 Spike (B.1.617.2; AY.3; AY.5; AY.6; AY.7; AY.14) <b>Alt Seq 1</b>	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (P.1)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000
SARS-CoV-2 Spike (B.1.1.7)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 - 1,000,000
SARS-CoV-2 Spike (B.1.351)	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 - 1,000,000
SARS-CoV-2 S1 RBD	≤ 18%	≤ 10%	≤ 13%	Pass	1,500 – 1,000,000

COA-16511-A QA-FM-303-B



#### **CERTIFICATE OF ANALYSIS**

Page 2 of 2

## **Coating Confirmation Testing Results:**

Spot	Description	Result
1	SARS-CoV-2 Spike	Pass
2	SARS-CoV-2 Spike (D614G)	Pass
3	SARS-CoV-2 Nucleocapsid	Pass
4	SARS-CoV-2 Spike (B.1.617.2; AY.3; AY.5; AY.6; AY.7; AY.14) <b>Alt Seq 1</b>	Pass
7	SARS-CoV-2 Spike (P.1)	Pass
8	SARS-CoV-2 Spike (B.1.1.7)	Pass
9	SARS-CoV-2 Spike (B.1.351)	Pass
10	SARS-CoV-2 S1 RBD	Pass

Note: Alternative S-GENE mutations for Spike of AY.1, AY.2, and B.1.617.2 are listed as "Alt Seq#."

## **Functional Testing Results:**

Sample Type	Calibrator	Controls		Samples	
Metric	Avg Signal Ratio Test:Reference	Control Recovery	Control Conc. CV	Avg % Difference Test:Reference	Slope Test:Reference
SARS-CoV-2 Spike	50 – 200%	70 – 130%	< 20%	± 25%	0.80 - 1.2
SARS-CoV-2 Spike (D614G)	50 – 200%	70 – 130%	< 20%	± 25%	0.80 - 1.2
SARS-CoV-2 Nucleocapsid	50 – 200%	70 – 130%	< 20%	± 25%	0.80 - 1.2
SARS-CoV-2 Spike (B.1.617.2; AY.3; AY.5; AY.6; AY.7; AY.14) <b>Alt Seq 1</b>	50 – 200%	70 – 130%	< 20%	± 25%	0.80 – 1.2
SARS-CoV-2 Spike (P.1)	50 – 200%	70 – 130%	< 20%	± 25%	0.80 - 1.2
SARS-CoV-2 Spike (B.1.1.7)	50 – 200%	70 – 130%	< 20%	± 25%	0.80 - 1.2
SARS-CoV-2 Spike (B.1.351)	50 – 200%	70 – 130%	< 20%	± 25%	0.80 - 1.2
SARS-CoV-2 S1 RBD	50 – 200%	70 – 130%	< 20%	± 25%	0.80 - 1.2

### **Additional Comments:**

Functional testing was executed using SARS-CoV-2 Plate 17 (Z0057190), SULFO-TAG Anti-Human IgG Antibody (D00V0025), Reference Standard 1 (A0080286), and Serology Controls (A00C0825, A00C0826, A00C0827).

All kit components were manufactured and tested according to MSD documents. The lots listed in the Kit Components table meet MSD's specifications.

#### **Statement:**

The above product is intended for Research Use Only. Not for use in Diagnostic Procedures.

	Name	Function	Signature	Date
Review/Approval	Karen Hamilla	Quality	Haur Hamille	20 JUN 2022

COA-16511-A QA-FM-303-B